Calmare Therapeutics (OTC: CTTC) researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. The company’s flagship medical device – the Calmare® Pain Therapy Device – is the only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. The company holds a FDA 510k clearance designation on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States. Calmare Devices are commercially sold to medical practices throughout the world. For more information, visit the company’s website at www.calmaretherapeutics.com